Pancreas Presentation

4,612 views
4,193 views

Published on

1 Comment
0 Likes
Statistics
Notes
  • Is this an Energex Systems' or an Arbios Systems' concept? Or has Energex Systems merged with Arbios Systems?
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • Be the first to like this

No Downloads
Views
Total views
4,612
On SlideShare
0
From Embeds
0
Number of Embeds
17
Actions
Shares
0
Downloads
112
Comments
1
Likes
0
Embeds 0
No embeds

No notes for slide

Pancreas Presentation

  1. 1. The PancreAssist System<br />A Bioartificial Pancreas<br />
  2. 2. Insulin-Glucose Relationship<br />Normal vs. Diabetic<br />Normal<br />Glucose<br />Insulin<br />Diabetic<br />Glucose<br />Insulin Injection<br />Insulin<br />B<br />L<br />D<br />S<br />
  3. 3. Diabetes<br />Irregular blood glucose level control leads to complications; insulin injections are currently only practical therapy<br />Insulin therapy fails to achieve consistent blood glucose; reliance on patient self-monitoring limits effectiveness <br />PancreAssist™ System designed to provide automatic, continuous blood glucose level control<br />Unmet Medical<br />Need<br />Shortcomings of<br />Current Therapy<br />ArbiosSolution<br />
  4. 4. PancreAssist SystemU.S. & Europe Market Potential<br />No. of Patients Market Potential*<br />100% of “Brittle” Diabetics 40,000 $ 200 million<br />50% of All Type I Diabetics 700,000 $3,500 million<br />10% of All Type II Diabetics 1,400,000 $7,000 million<br /> * Assume one device/reseeding per patient, per year at $5,000 each<br />
  5. 5. The PancreAssist System<br />A Bioartificial Pancreas<br />Objective<br />To develop an implantable device <br />containing pancreatic islets <br />to improve blood glucose control<br />in insulin-dependent diabetics<br />
  6. 6. Bioartificial Pancreas<br />Device Types<br />I<br />I<br />I<br />Blood<br />G<br />G<br />I<br />Artery<br />Vein<br />I<br />I<br />Perfusion Device<br />Pancreatic Islets<br />Membrane<br />G = Glucose I = Insulin<br />G<br />G<br />I<br />I<br />I<br />I<br />G<br />G<br />Tissue<br />Diffusion Device<br />
  7. 7. Insulin<br />Pancreatic Islets<br />Blood<br />Blood<br />Ultrafiltration Hollow Fiber<br />Glucose<br />in<br />Antibodies<br />out<br />White Cells<br />Insulin<br />PancreAssist™ System<br />Bioartificial Pancreas<br />Semipermeable<br />Membrane Coil<br />Islet <br />Seeding Ports<br />Porcine Islets<br />Device Housing<br />PTFE<br />Vascular Graft<br />Device Schematic<br />
  8. 8. Reseedable PancreAssist™ System<br />
  9. 9. Key Advantages of Technology<br />General<br /><ul><li>Biocompatible & Immunoprotective Membranes
  10. 10. Non-transformed, Primary Cells
  11. 11. Normal Cell Functions</li></ul>PancreAssist™ System<br /><ul><li> Direct Blood Contact for Optimum Oxygen Supply
  12. 12. Rapid Insulin Release
  13. 13. Physiological Blood Glucose Feedback
  14. 14. No Anticoagulation or Immunosuppression</li></li></ul><li>Experimental Protocol<br />Total Pancreatectomy<br />Islet Isolation<br />(10-20 kg dog)<br />Seeding of<br />Seeding of<br />2-3 weeks<br />in vivo Device<br />in vitro Device<br />Device<br />Continuous<br />Implantation<br />Perfusion<br />Control of Hyperglycemia<br />Insulin Output<br />
  15. 15. ARTIFICIAL PANCREASCanine Islets in Diabetic Dog<br />Pancreatectomy<br />Device Implanted<br />Single Gen. 8 / PS-10<br />
  16. 16. ARTIFICIAL PANCREAS DEVICECanine Islets in Diabetic DogTwo Devices Implanted<br />Pancreatectomy<br />Devices<br />Devices<br />Implanted<br />Removed<br />PS-56<br />
  17. 17. Device Implanted<br />Device Explanted<br />PancreAssist System<br />Xenogeneic Bioartificial Pancreas<br />Porcine Islets in Diabetic Dog<br />
  18. 18.
  19. 19. PancreAssist System<br />Pre-clinical Studies<br />Device Patency<br /><ul><li> Implanted 11 device designs in over 250 animals
  20. 20. Achieved device patency for up to 4 years in large</li></ul> animal model without anticoagulation<br /><ul><li> Patency rate comparable to same size grafts in </li></ul> humans<br />Cells<br /><ul><li> Porcine islet process established</li></li></ul><li>PancreAssist System<br />Pre-clinical Studies<br />Device Function<br /><ul><li> Improved blood glucose control
  21. 21. Reduced need by up to 75% for exogenous insulin </li></ul> for nine months in diabetic dogs<br /><ul><li> No immunosuppression required</li></ul>Summary<br /><ul><li> Because no immunosuppression is required, </li></ul> the BAP may be used prior to the development <br /> of diabetic complications<br />
  22. 22. PancreAssist SystemDevelopment Plan<br /><ul><li> Establish joint development collaborations to share risk and expand capability in:</li></ul>- Pancreatic beta cell line development<br />- Implantable device technology<br />- Medical device marketing & sales<br />

×